Balloon sinus dilation treatment Entellus Medical files for a $69 million IPO

Entellus Medical, which sells a minimally invasive balloon sinus dilation treatment to open obstructed sinus pathways, filed on Tuesday with the SEC to raise up to $69 million in an initial public offering.

The Plymouth, MN-based company, which was founded in 2006 and booked $45 million in sales for the 12 months ended September 30, 2014, plans to list on the NASDAQ under the symbol ENTL. Entellus Medical initially filed confidentially on October 7, 2014. BofA Merrill Lynch and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.